Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives

Roberto Baldelli1*, A. Barnabei1, L. Rizza2, A. M. Isidori2, F. Rota1, P. Di Giacinto3, A. Paoloni1, F. Torino4, S. M. Corsello5, A. Lenzi2 and M. Appetecchia1

1 Endocrinology Unit, Regina Elena National Cancer Institute, Rome, Italy
2 Section of Endocrinology, Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy
3 Section of Reproductive Endocrinology, Department of Systems Medicine, Tor Vergata University of Rome, Fatebenefratelli Hospital, Rome, Italy
4 Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
5 Department of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy

*Correspondence: Roberto Baldelli, Endocrinology Unit, Regina Elena National Cancer Institute, via Elio Chianesi, 53, Rome, 00144 Italy. E-mail: baldelli@ifo.it

INTRODUCTION

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present many clinical features secreting peptides and neuroamines that cause distinct clinical syndromes such as carcinoid syndrome. However most of them are clinically silent until late presentation with mass effects. Surgical resection is the first line treatment for a patient with a GEP-NET while in metastatic disease multiple therapeutic approaches are possible. GEP-NETs are able to express somatostatin receptors (SSTRs) bounded by somatostatin (SST) or its synthetic analogs, although the subtypes and number of SSTRs expressed are very variable. In particular, SST analogs are used frequently to control hormone-related symptoms while their anti-neoplastic activity seems to result prevalently in tumor stabilization. Patients who fail to respond or cease to respond to standard SST analogs treatment seem to have a response to higher doses of these drugs. For this reason, the use of higher doses of SST analogs will probably improve the clinical management of these patients.

Keywords: neuroendocrine tumors, somatostatin analogs, lanreotide, octreotide, carcinoid

www.frontiersin.org

February 2014 | Volume 5 | Article 7 | 1
somatostatin and dopamine receptors

Table 1 | Somatostatin receptors in neuroendocrine gastroenteropancreatic tumors (%).

| Tumor                  | SSTR1 | SSTR2 | SSTR3 | SSTR4 | SSTR5 |
|------------------------|-------|-------|-------|-------|-------|
| All                    | 68    | 86    | 46    | 93    | 57    |
| Insulinoma             | 33    | 100b  | 33    | 100   | 67    |
| Gastrinoma             | 33    | 50    | 17    | 83    | 50    |
| Glucagonoma            | 67    | 100   | 67    | 67    | 67    |
| VIPoma                 | 100   | 100   | 100   | 100   | 100   |
| N-F                    | 80    | 100   | 40    | 100   | 60    |

IP, vasoactive intestinal polypeptide; N-F, non-functioning.

*Using receptor subtype antibodies.

Modified from Oberg et al. (13).

SSTRs expression while 100% of somatostatinomas expressed SSTR 5 and 100% of gastrinomas and glucagonomas expressed SSTR 2 (13). SST is a natural peptide hormone secreted in various parts of the human body, including the digestive tract, able to inhibit the release of numerous endocrine hormones, including insulin, glucagon, and gastrin. The biological effects of SST are mediated through its specific receptors (SSTRs 1–5) all bind natural peptides (SST-14, SST-28, and cortistatin) with similar high affinity. However, endogenous SST short half-life in circulation (1–3 min), makes it difficult to use it continuously and has resulted in the development of synthetic analogs from the early 1980s when a number of short synthetic analogs of SST including SMS201-995 (octreotide), RC-160 (vapreotide), BIM 23014 (lanreotide), and MK 678 (seglitide) were developed. These cyclic octapeptides are more resistant to peptidases and their half-lives and hence their biological activities are substantially longer than native SST (1.5–2 h vs. 1–2 min) (14). Moreover the development of a depot formulation of octreotide [octreotide long-acting repeatable (LAR)], administered up to 30 mg once every 4 weeks has a large extent eliminated the need for daily injections. Lanreotide SR (slow release) 30, 60, and 90 mg formulations administered every 10–14 days, has a similar efficacy to octreotide in the treatment of carcinoid tumors (15). A new slow release depot preparation of lanreotide, lanreotide autogel, is administered subcutaneously up to 120 mg once a month (16). Native SST and its synthetic analogs show different affinity for the five specific SSTRs (11, 12, 17). Native SST binds all the five receptor subtypes (SSTRs 1–5). The effects of the SST analogs are mediated by the interaction with SSTR 2 and 5 receptors while the new SST analog, pasireotide (SOM 230), shows higher binding capacity toward SSTRs 1, 2, 3, and 5 with no agonist activity at the type 4 receptor (17) (Table 3). Moreover, in vitro studies demonstrated that SOM 230 was more effective than octreotide to control cell proliferation and apoptosis (18). The different receptor subtypes binding affinities seems to result in different biological and clinical activities (12).

**THE SYMPTOMATIC AND BIOCHEMICAL EFFECTS OF SST ANALOGS**

Gastroenteropancreatic neuroendocrine tumors first line therapy, where possible, is always an aggressive surgical approach, aimed to obtain a curative tumor ablation, even in the presence of metastatic disease. However, in patients with functioning or metastatic tumors, the treatment goal is to improve their quality of life trying to alleviate the tumor associated symptoms and increasing survival (2, 14, 15). Recently, the diagnostic and therapeutic approach of GEP-NETs has considerably improved, mainly due to better imaging techniques (CT, MRI, PET) and SST analog-based imaging methods, as well as receptor subtype characterization and the introduction of long-acting SST analogs (21–27). Usually, the treatment with long-acting preparations of SST analogs consists in an intramuscular injection (i.m.) every 2 or 4 weeks (octreotide-LAR, 10–30 mg; lanreotide autogel 60–120 mg) and the efficacy in the control of symptoms is well-documented (2, 14, 15). Recently, the diagnostic and therapeutic approach of GEP-NETs has considerably improved, mainly due to better imaging techniques (CT, MRI, PET) and SST analog-based imaging methods, as well as receptor subtype characterization and the introduction of long-acting SST analogs (21–27). Usually, the treatment with long-acting preparations of SST analogs consists in an intramuscular injection (i.m.) every 2 or 4 weeks (octreotide-LAR, 10–30 mg; lanreotide autogel 60–120 mg) and the efficacy in the control of symptoms is well-documented (2, 14, 15), even if patients with islet cell tumor often show a transient (median time 2.5 months) and non-significant response (21–27). The drugs are safe and well-tolerated in both long- and short-term treatments (28–32). However, after 9–12 months, drug resistance...
Table 3 | Somatostatin receptor subtype-binding affinity of somatostatin analogs.

| Compound           | SSTR1 | SSTR2 | SSTR3 | SSTR4 | SSTR5 |
|--------------------|-------|-------|-------|-------|-------|
| Somatostatin-14    | 2.26  | 0.23  | 1.43  | 1.77  | 0.88  |
| Somatostatin-28    | 1.85  | 0.31  | 1.3   | ND    | 0.4   |
| Octreotide         | 1140  | 0.56  | 34    | 7030  | 7     |
| Lanreotide         | 2330  | 0.75  | 107   | 2100  | 5.2   |
| Pasireotide        | 9.3   | 1     | 1.5   | >100  | 0.16  |

ND, not determined.
Modified from Ref. (20).

should appear and patients may show the symptoms of recrudescence. In such cases the approach proposed was to continue the treatment by increasing the analog dosage or by shortening the administration range (33). A randomized double-blind trial compared long-acting octreotide-LAR at 10, 20, and 30 mg every 4 weeks with open-label short-acting octreotide every 8 h for the treatment of carcinoid syndrome. It showed that the efficacy of short-acting octreotide and of the long-acting octreotide-LAR was the same once circulating octreotide steady-state concentrations were achieved (34). O’Toole et al. in a multicentre study on 33 patients with the carcinoid syndrome comparing the treatment with lanreotide (30 mg i.m. every 10 days) vs. octreotide (200 µg s.c. twice or thrice daily) founded no significant differences in controlling symptoms (53.8 and 45.4%, respectively). Lanreotide and octreotide may also significantly lower the levels of the catabolite of serotonin (urinary 5-hydroxyindoleacetic acid/5-HIAA) (35). Ruszniewski et al. evaluated the efficacy and safety of the 28-day- aqueous prolonged release formulation of lanreotide in 75 patients in a 6-month-dose titration study where 30% of patients showed a biochemical response and 75 and 80% of patients reported resolution of diarrhea and flushing, respectively. The median decrease in levels of urinary 5-HIAA and serum chromogranin A was 24 and 38%, respectively (36). An interim analysis of a phase II trial of SOM230 in 21 patients with metastatic carcinoid tumors whose symptoms (diarrhea and flushing) were refractory/resistant to octreotide-LAR showed symptom relief in 33% (37). Approximately 10–15% of patients with midgut carcinoids suffer from watery diarrhea, flushing, right-sided heart failure, and bronchial constriction (carcinoid syndrome), due to the tumor hypersecretion of a variety of endocrine substances, the most frequent of which are serotonin (5-hydroxytryptamine) and the tachykinins (38, 39), and therefore SST analogs are important palliative tools for these patients. In insulinoma it has been noted that octreotide treatment may induce hypoglycemia worse in those patients lacking SSTRs 2 and 5, and as glucagon secretion is also inhibited, patients have to be observed closely at the beginning of therapy to prevent severe hypoglycemia due to the reduced glucagon-dependent counter-regulation (19). Hence, this treatment has to be started in a hospital setting, and should be reserved only for the minority of insulinoma patients with positive imaging on SRS. Vezzosi et al. recently assessed that octreotide was effective in the control of hypoglycemia in more than 50% of the insulinoma patients (40). The treatment was effective in all SSTR 2 positive patients and in a few SSTR 2 negative ones, while no relation between treatment effectiveness and the expression of SSTR 5 was observed (40). These results are in concordance with other case reports and smaller series of insulinoma patients reported in the literature (41–45). In glucagonoma patients SST analog treatment is indicated to reduce the symptoms related to the characteristic skin rash (neurotectic migratory erythema) or diarrhea (46–50). Somatostatinomas symptoms are due to SST hypersecrec- tion (hyperglycemia, cholelithiasis, diarrhea and steatorrhea, and hypochlorhydria) or to the mass effect (51). Although it seems a paradox to treat patients with symptoms related to elevated SST levels with a somatostatinoma, in 1998 Angeletti et al. showed that octreotide treatment was effective in reducing SST plasma levels and improving the related symptoms in three patients with metastatic somatostatinomas (52). Furthermore, nine cases of VIPoma have been described in which octreotide was very successful as adjuvant therapy for symptoms control and for reducing the serum elevated VIP levels by improving the diarrhea and the electrolyte imbalance (53–55).

THE ANTI TUMOR EFFECTS OF SST ANALOGS

The anti-neoplastic activity of SST analogs has been demonstrated in several experimental models in vivo and in vitro (56–61) but it is still little known regarding the anti-proliferative role of SSA in GEP-NETs, although increasing data suggest that such analogs can be tumoristic, at least in some circumstances (62). The antineoplastic action of SST analogs depends on the kind of tumor and the receptor subtypes to which they are bound to and occurs through direct and indirect mechanisms. While direct activities are mediated by specific membrane receptors and include anti- mitotic and apoptotic effects, indirect effects do not depend on the receptor binding but depend on the growth factor inhibition, antiangiogenic, and immuno-modulating activities. SST analogs are able to inhibit the growth of Swarm chondrosarcoma, used as experimental model of SSTR free tumor (63). The mitosis inhibition is mediated by SSTRs 2 and 5 and results in the cell cycle arrest (56). The loss of the SSTR 2 expression in some human adenocarcinomas seems to be responsible for loosing the regulation of cell proliferation (10–19, 21–64). The loss of SSTR 2 may consequently promote tumor growth and make it clear the therapeutic inefficacy of SST analogs in such kind of neoplasia. Apoptosis seems to be induced by two different processes: interaction with the SSTR 3 (57) and inhibition of the Insulin-like Growth Factor I (IGF I), known as a potent antiapoptotic hormone (65). The pro-apoptotic activity of SST analogs seems to have clinical relevance, as shown by the interesting findings published by Eriksson et al. that reported an increase in apoptosis in biotic samples of tissues by patients with GEP-NETs after the treatment with SST analogs at high doses. It followed that apoptosis is related to the biochemical response and the disease stabilization (70% of cases) (66, 67). However, Fais et al. observed an overall response rate (ORR) of 6.7%, comparable to that recorded at conventional doses (68), in 24 patients with GEP-NETs treated with high doses of lanreotide (15 mg/day). The indirect anti-proliferative efficacy of SST analogs is shown by an antiangiogenic mechanism. Tumor angiogenesis is essential in the development and metastatic spread...
of tumors, so the growth can be actually controlled by reducing the vascularization of the neoplastic tissue. In experimental models, octreotide shows a strong antiangiogenic effect, which is probably mediated by the inhibition of the Vascular Endothelial Growth Factor (VEGF) (69–71). The treatment with octreotide would result in a significant reduction in VEGF levels compared to the baseline, since it is related to the survival of the patients (71). It was observed that endothelial cells do not express the SSTR 2 that is present on the contrary, when they proliferate in order to form blood vessels. This could represent further opportunity to treat patients with octreotide that is able to recognize and inhibit new vessel formation both alone and with other drugs, thanks to its high affinity with such receptor (Table 3). Immunomodulation is another indirect mechanism of action of SST analogs. Preliminary evidence suggests that they stimulate the production of immune system components with antitumor effect, such as natural killer cells (72, 73), even if up to now it is not clear whether this can be clinically significant thus helping the antitumor efficacy of SST analogs. Few data exist on the functions mediated by the SSTR 4. Beclin1 evidence suggests that they stimulate the production of immune system components with antitumor effect, such as natural killer cells (72, 73), even if up to now it is not clear whether this can be clinically significant thus helping the antitumor efficacy of SST analogs. Few data exist on the functions mediated by the SSTR 4. However, no unanimity exists about the SST analog ability to control (i.e., to slow) the tumor progression. In vitro studies reported that the response of different cell lines to the octreotide exposition produces a biphasic dose–response curve (74, 75). Consequently, overdose or underdose of SST analogs may result in a suboptimal anti-neoplastic activity. Nevertheless, the negative results of some clinical studies in terms of tumor response could be due to the administration of too low doses to achieve receptor optimal saturation. After all, in other studies that used octreotide doses higher than 8 mg/day and lanreotide doses higher than 10 mg/day (76), no improvement of the SST analog antitumor effect was observed. No study on the tumor response monitored plasma levels of an SST analog up to now, in order to assess that optimal drug therapeutical levels are reached but not exceeded (77). Tumor shrinkage was demonstrated in <10% of the patients. However, a stabilization of tumor growth occurs in up to 50% of the patients with neuroendocrine tumors of various locations. Stable disease was observed in 37–45% of the patients with documented tumor progression before SSA therapy (Table 4). The median duration of stabilization was 26.5 months (31,78–81). In a study on a selected group of patients with progressive disease, in the 47% of cases was demonstrated a stable disease when treated with a high dose of lanreotide (3–5 g/day) (82). This result has been confirmed in patients with advanced midgut carcinoids, who had a stabilization of the disease for 6–24 months in the 75% of cases (83). One patient with a pancreatic primary tumor and distant extrahepatic metastases, showed a poor response to treatment in multivariate analysis. Age, size of the primary tumor, and Ki67 did not influence the response rate to SSA therapy (81). A stabilization of the disease was maintain throughout long-term follow-up in patients who achieve it after 6 months of treatment; these patients live longer than those unresponsive to therapy (81, 84). Very recently, Rinke et al performed for the first time a placebo-controlled, double-blind, and phase III B study in 85 patients with well-differeniated metastatic midgut NETs using octreotide-LAR 30 mg intramuscularly in monthly intervals (PROMID study). Median time to tumor progression in the octreotide-LAR and placebo groups was 14.3 and 6 months, respectively. After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide-LAR group and 37.2% of patients in the placebo group. Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor. Octreotide-LAR significantly lengthened the time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs (85). Midgut carcinoids express SSTRs in 80–100% of cases and SSTR 2 is the most frequently expressed (39). The anti-proliferative effect of SST analogs on the growth of the midgut carcinoids is unknown. A partial or complete responses were observed in <10% of the patients, while stabilization of tumor growth was noticed in 24–57% of the patients (6). Few data are available regarding the role of SST analogs in the treatment of gastrinomas. In a study of 15 malignant gastrinoma, in about 50% of these patients, octreotide had an anti-proliferative effect, including one patient with tumor regression and seven patients with tumor stabilization (mean period 25 months) patients (86). The long-acting SST analog octreotide-LAR was administered in a patient with multiple type A gastric carcinoids for a period of 9 months with a normalization of serum gastrin levels and permanent disappearance of the tumor (87). Fykse et al. treated five patients with hypergastrinemia and gastric carcinoids for a period of 10 months with a significant reduction in serum gastrin. A complete remission was achieved in 3 patients (88).

Table 4 | Anti-proliferative effect of somatostatin analogues in patients with progressive disease.

| SSA             | Dosagen (µg/day) | n  | CR | PR | SD | PD | Reference |
|-----------------|-----------------|----|----|----|----|----|-----------|
| Lanreotide      | 3000            | 22 | 0  | 1  | 7  | 14 | (83)      |
| Lanreotide      | 30 mg/2 weeks   | 35 | 0  | 1  | 20 | 14 | (81)      |
| Octreotide      | 600/1500        | 52 | 0  | 0  | 19 | 33 | (76)      |
| Octreotide      | 1500/3000       | 58 | 0  | 2  | 27 | 29 | (28)      |
| Lanreotide      | 15000           | 24 | 1  | 1  | 11 | 11 | (83)      |
| Octreotide      | 600             | 10 | 0  | 0  | 5  | 5  | (74)      |
| Octreotide median dose of 250 µg three times daily | 34 | 0 | 1 | 17 | 0 | (76) |
| Octreotide-LAR 30/lanreotide SR 60 mg/28 days | 31 | 0 | 0 | 14 | 4 | (77) |
| Total           |                 | 256| 1  | 6  | 115| 105|           |
| Percentage (%)  |                 | 0.3| 2  | 45 | 41 |     |           |

CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
of 1 year with monthly injections of octreotide-LAR with a significant reduction in tumor load, entero-chromaffin-like cells (ECL) cell density, and normalization of circulating chromogranin A levels, indicating a possible direct anti-proliferative effect of the treatment (88). These results suggest that the SST analogs could have an important anti-proliferative effect. However, data on the effect of SST analogs on tumor growth in patients with gastric carcinoids type C or poorly differentiated endocrine carcinomas are scanty. In poorly differentiated gastric carcinomas, treatment with SST analogs is not considered. As surgical excision is the definitive treatment of insulinoma, there are few contrasting data in the literature regarding the inhibitory effect of the SST analogs on the growth of these tumors. Grozinsky-Glasberg et al. have conducted a study regarding the effects of SST analogs on cell proliferation in the rat-derived insulinoma cell line (INS1). Their preliminary data show that octreotide has a significant inhibitory effect on cell proliferation, as assessed by cell counting and MTS assay, and on phosphorylation states of a number of proteins in the PI3K/Akt/mTOR pathway (89, 90). In his work, Vezzosi founded that despite achieving hypoglycemic control, insulinoma size remained unchanged or increased moderately despite normal blood glucose levels, concluding that SST analogs, as medical treatment is not sufficient to prevent tumor growth in patients with malignant insulinomas (40). In 2006, Romeo et al. reported a complete clinical remission with regression of the metastatic lesions in the liver after 1 year in a patient affected by metastatic insulinoma with severe hypoglycemia treated with octreotide-LAR (90). A more controversial area concerns the treatment of patients with non-functioning endocrine tumors of the pancreas as few studies have been published in these patients. The prospective German Sandostatin multicentre phase II trial investigated the effects of octreotide for 1 year on tumor growth in 103 patients and included 15 patients with diagnosed non-functional pancreatic tumors (79). Only 3 out of these 15 patients had a stable disease, in 8 patients a tumor progression occurred while the outcome of the remaining 4 patients was not clear. As previously reported, the SST analog efficacy depends on the tumor receptor expression patterns, but these are rarely assessed, even if there is evidence of better results on survival obtained with selective treatments. An anti-proliferative effect was achieved on hepatic metastatic cells in a patient with a carcinoid tumor, selected for the treatment with SST analogs after the immunohistochemical identification of the SSTRs 1, 2, and 5 subtypes expression on the neoplastic cell surface (91). A complete clinical remission with regression of the metastatic lesions in the liver after 1 year of treatment was observed in a patient affected by metastatic insulinoma with severe hypoglycemia treated with octreotide-LAR expressing at immunohistochemical analysis of tissue specimens a strong membrane immunoreactivity for SSTR 2 in both the primary nodule and the metastases (90). However, another study showed neither an anti-neoplastic effect nor an increase in survival percentage of treated patients (92). It has been reported that in glucagonoma patients there are no data available on their SSTR expression patterns (49). In 2006 we demonstrated, for the first time, a scattered immunopositivity for SSTRs in a case of malignant glucagonoma. We had access to polyclonal antibodies specifically targeted against SSTR5 and SSTR2 and we were therefore able to localize these two receptors in our histological sections. The immunopositivity was detected for both receptor subtypes in the membrane and in the cytoplasm of glucagonoma cells. We then treated our patient with a combination therapy consisting of the SST analog octreotide and interferon-α. The patient had a complete resolution of skin rash, normalization of plasma glucagon, chromogranin A, and neuron specific enolase levels and a metastatic disease stabilization. The patient’s quality of life significantly improved, and she was alive 40 months after debulking surgery (50).

**THE EFFECTS OF HIGHER THAN USUAL DOSE OF SST ANALOGS**

It was suggested that higher than usual dose of SST analogs treatments (>3,000 μg/day) may promote the anti-proliferative effect, especially in those patients responding to standard doses (2, 17, 18, 83, 94, 95). A high-dose treatment with lanreotide (up to 12 mg/day) produced tumor size reduction in 5% and stabilization in 70% of the 19 patients. An induction of apoptosis in the tumors was observed in responding patients, a phenomenon not seen with regular doses of SST analogs, but often produced by chemotherapeutic agents (67). Subcutaneously injections of 5 mg lanreotide three times a day for a period of 1 year produced one complete and one partial remission (PR) in 30 patients with functional midgut NETs; stable disease in 11 patients (36%) and progression of the disease after 3–12 months of treatment in 11 patients (68). The treatment with high-dose SST analogs induced apoptosis in neuroendocrine tumors, while this was not found during treatment with low-dose SST, in a study where biopsy specimens were taken before and during SST analog treatment (66). In a highly select group of patients with progressive disease, 47% of the patients demonstrated at least stable disease when treated with a high dose of lanreotide (3–5 g/day) (82). High-dose formula of octreotide has been recently reported to stabilize hormone production and tumor growth in 75% of patients with advanced midgut carcinoid tumors and progressive disease with stabilization for 6–24 months (83). These effects may be attributable to SSTR 2, which is the most frequently expressed subtype and/or SSTR 5, 1, and 3 that are also expressed (96, 97). Data from a study with ultra-high-dose octreotide pamoate (Onco-LAR; Novartis) at 160 mg intramuscularly every 2 weeks for 2 months followed by the same dose once monthly, appear to show some promise. Tumor size stabilization was obtained in 12 patients, a biochemical responses in 9 patients and/or stability in 11. No significant tumor reduction was noted. At 6 months, the median plasma concentrations of octreotide were 25–100 times higher than those obtained by using octreotide-LAR at regular doses. A significant inhibition of angiogenesis was also showed through the down-regulation of proliferative factors such as VEGF and fibroblast growth factor (14). The highest response rates were reported using octreotide in doses >30 mg/day or lanreotide in doses >5 mg/day (and up to 15 mg/day) (64). Tomasetti et al. have reported that after 1-year therapy, the tumor completely disappeared in three patients suffering from gastric carcinoid, two of whom were treated with lanreotide 30 mg i.m. every 10 days (98). In a recent paper it was reported that in patients with Hashimoto’s thyroiditis presenting ECL hyperplasia, considered a
Baldelli et al. Somatostatin analogs treatment in GEP-NET pre-neoplastic mark, the treatment with SST analog for 12 months resulted into the disappearance of ECL lesions (93). SST analogs can have a role in the treatment of digestive neuroendocrine tumors with low grades of malignancy, a low cellular proliferation index and high specific receptorial density in vivo as reported by Bombardieri et al. (29). In a very complete and well design paper of Ferolla et al. patients with well-differentiated neuroendocrine tumors, were treated with long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days; the end point of this study was to evaluate a different schedule of octreotide-LAR administration consistent with a shorter interval between administrations (21 days) in patients with a progressive disease at standard-dose interval. For this reason 28 patients who had tumor progression during therapy with LAR 30 mg every 28 days were enrolled. Clinical, biological, and objective tumor response was evaluated after LAR 30 mg every 21 days. Time to progression was also evaluated after LAR 30 mg every 21 days and compared to LAR 30 mg every 28 days. The treatment with LAR 30 mg every 21 days resulted in complete and partial control of clinical symptoms in 40 and 60% of cases, respectively. Circulating neuroendocrine markers were significantly decreased in 30% of cases. A stabilization of disease was obtained in 93% and objective response in 7%. The median time to progression was significantly longer by using the shortened interval of LAR administration as compared to the standard one (21 days vs. 9 months, \( p < 0.0001 \)) and the treatment was safe and well-tolerated. The authors conclude that the shortened schedule of LAR administration was able to re-institute control of clinical symptoms, to decrease level of circulating neuroendocrine markers and to increase time to progression in patients previously escaping from a standard schedule treatment (99).

**SOMATOSTATIN ANALOGS AND DIAGNOSTIC/ThERAPEUTIC NUCLEAR MEDICINE**

Somatostatin receptors are able to form a receptor–ligand complex permitting the internalization and the accumulation of the radiopharmaceutical peptide inside the tumor using this procedures for diagnosis and radiometabolic treatments of these tumors (Figure 2). Peptide-receptor radionuclide therapy (PRRT) is an important treatment strategy for tumors that express adequate densities of SSTRs and has proven to be safe and effective. It was initially performed using indium-111 (24, 100). Recently, the development of SST peptides with higher receptor affinity conjugated with radio-metal labeling chelators, such as DOTA, which may be allow stable labeling with gallium, yttrium, or lutetium, changing the affinity profile for particular subtypes of SSTRs can permit new therapeutic options (101). Waldherr et al. evaluated the tumor response to targeted irradiation with the radiolabeled SST analog \( ^{90} \)Y-DOTATOC in 41 patients with GEP-NET and bronchial tumors. They reported an ORR of 24%. For endocrine pancreatic tumors it was 36%. A complete remission was found in 2%, a PR in 22%, a minor response in 12%, stable disease in 49%, and progressive disease in 15% of patients. The treatment was well-tolerated and there was a significant reduction of symptoms and the 2-year survival time was 76 ± 16% (102). 177Lu DOTATATE \[ {^{177}	ext{Lu}}	ext{DOTA-Tyr}(3)-octreotate, a selective analog of SSTRs 2, in spite of its favorable affinity profile, at its maximum tolerated dose, it is limited by toxic effects on the kidney and bone marrow.**

**FIGURE 2** | PET gallium 68 DOTATOC showing the presence of multiple liver metastasis from neuroendocrine ileal tumor.
Nevertheless, the results seem encouraging compared with historical therapeutic data (103). Kwekkeboom et al. obtained promising results using 177Lu DOTATATE [177Lu]DOTA-Tyr(3)-octreotate in 131 patients with NETs. A complete remission was observed in 2% of patients, a PR in 26%, a minor response in 19%, stable disease in 35%, and progressive disease in 18% of patients. Higher remission rates were positively correlated with high uptake on pre-therapy SSTRs imaging, whereas progressive disease was significantly more frequent in patients with extensive disease. Median time to progression was more than 36 months (24). The combination of 90Y- and 177Lu-labeled analogs (104) seems to have had superior antitumor effects when compared with either 90Y- or 177Lu-analog in animals presenting with tumors of various sizes. It has been reported that 177Lutetium may be more effective for smaller tumors whereas 90Ytrium may be more effective for larger tumors (105, 106).

**Somatostatin analogs and interferon**
The combination of SSAs and interferon (IFN) has been used in an effort to enhance the anti-proliferative effect of IFN therapy, to add the positive effect of SSAs on hypersecretory syndromes, and to reduce the dose of IFN and thus the number of IFN-related side-effects. Whether SST analogs and IFN show a synergistic effect on tumor growth and in carcinoid syndrome symptom management is matter of debate. The combination therapy with SST analogs and IFN is in fact limited by the small number of trials, with variable results. This combination seems of benefit in patients where the usual octreotide treatment failed to achieve a biochemical and symptomatic control (107).

**Conclusion**
Neuroendocrine tumors of the gastroenteropancreatic (GEP-NETs) system comprise a rare group of malignant neoplasms. The SST analogs have been shown to be very useful for symptomatic and biochemical improvement in patients with these tumors while preclinical and clinical studies provide conflicting results on their antitumor effects. The mechanisms of these effects are unknown, but probably are in part due to direct effects on proliferative signaling pathways, activation of apoptosis, and effects on angiogenesis. Biological response to SST analogs depends on distribution and level of expression of SSTRs subtypes in tumors, and the expression of selective SSTR-signaling pathway molecules. The high density of SSTR 2 in endocrine tumors explains the use of SSTR 2 specific analogs in the diagnosis and treatment of these tumors. However, the role of SSTR 1, 3, and 5 appears to be of increasing interest. The development of new peptidic and non-peptidic SST analogs, subtype selective agonists, chimeric analogs, or pan-SST analogs appears to be a significant progress in the treatment of GEP-NETs but data are limited, mainly about the best time for its administration, or what is the most appropriate radioligand/combination to be used for each patient, and if and how the doses should be fractionated. Novel strategies based on SSTR 2 receptor gene transfer to target tumor growth and angiogenesis might offer new perspectives of therapeutic interest mainly to treat unresectable tumors. Prospective studies including large number of patients regarding the optimal dosage and modes of administration of SST analogs and the development of new slow release, SSTR subtype specific compounds are needed.

**References**
1. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut (2003) 54(Suppl 4):v1–16. doi:10.1136/gut.2003.053114
2. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 9(1):61–72. doi:10.1016/S1470-2045(07)70410-2
3. Pears AE. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochim Cytochem (1969) 17:303–13. doi:10.1389/jhc.1969.17.3.303
4. Solcia E, Kloppel G, Sobin LH. Histological Typing of Endocrine Tumours. World Health Organization International Histological Classification of Tumours, Second Edition. Heidelberg: Springer (2000).
5. Pape UE, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNNM classification system for upper gastrointestinal neuroendocrine tumors. Cancer (2008) 113(2):256–65. doi:10.1002/cncr.23549
6. Plockinger U, Gantzel N, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2004) 80(6):394–424. doi:10.1159/000085237
7. Beneyto M, Morris HM, Rovensky KC, Lewis DA. Labina- and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia. Neuropharmacology (2012) 62(3):1598–605. doi:10.1016/j.neuropharm.2010.12.029
8. Pasquali D, Notaro A, Bonavolonta’ G, Vassallo P, Bellastella A, Sinisi AA, Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab (2002) 87(11):5125–9. doi:10.1210/jc.2002-020790
9. Reski JG, Laisse J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol (1992) 43(1–3):27–35. doi:10.1016/0960-0760(92)90184-K
10. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res (1996) 56(8):1823–7.
11. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Tetti C, et al. The clinical-pathophysiological implications of the concept. J Histochem Cytochem (1969) 17:303–13. doi:10.1389/jhc.1969.17.3.303
12. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 9(1):61–72. doi:10.1016/S1470-2045(07)70410-2
13. Pears AE. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochim Cytochem (1969) 17:303–13. doi:10.1389/jhc.1969.17.3.303
14. Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology (2004) 80(1):57–63. doi:10.1159/000080743
15. Oberg K, Klovå L, Caplin M. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the
gastroenteropancreatic system. Ann Oncol (2004) 15(6):966–73. doi:10.1093/annonc/mdh216

16. Antonijans RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Valles J, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol (2004) 56(4):471–6. doi:10.1211/0022357023123

17. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol (2002) 146(5):707–16. doi:10.1530/ej.0.1460707

18. Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bells A. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol (2008) 40(6):263–71. doi:10.1677/JME-08-0012

19. Plockinger U. Biotherapy. Best Pract Res Clin Endocrinol Metab (2010) 24:145–62. doi:10.1016/j.beem.2007.01.002

20. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer (2008) 15(3):701–20. doi:10.1677/ERC-07-0288

21. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Leby AJ, et al. Somatostatin receptor imaging for neuroendocrine tumours. Pituitary (2006) 9(3):243–8. doi:10.1007/s11102-006-0270-5

22. Janson ET, Kalkner KM, Eriksson B, Westlin JE, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumours. Nucl Med Biol (1999) 26(8):877–82. doi:10.1016/S0969-8051(99)00059-1

23. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol (1999) 10(Suppl 2):S523–9. doi:10.1023/A:1027396313397

24. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabelled somatostatin analog (177Lu-DOTA0, Tyr3)octreotate A:1027396313397. Eur J Endocrinol (2008) 159(4):477–82. doi:10.1530/EJE-07-0367

25. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogues in the treatment of neuroendocrine tumors. Pituitary (2005) 8:145–62. doi:10.1002/(SICI)1097-0142(2005)2:4<145::AID-CNCR6>3.0.CO;2-0

26. Lanske B, Lerner M, Pravata R, Tafuro D, Farkas A, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 17(2):600–6.

27. O’Toole D, Ducruex M, Bommelager G, Weneau JL, Bouché O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer (2000) 88(4):770–6. doi:10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0

28. Ruszniewski P, Ish-Shalom S, Wymenga M, O’Toole D, Arnold R, Tomasetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged release formulation of lanreotide. Neuroendocrinology (2004) 80(4):244–51. doi:10.1159/000082875

29. Kools LR, Oberge KE, O’Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumours refractory or resistant to octreotide LR: results from a phase II study. Endocr Relat Cancer (2012) 19(5):657–66. doi:10.1530/ERC-11-0367

30. Kalke MH, Mayer RJ. Carcinoid tumors. N Engl J Med (1999) 340:858–68. doi:10.1056/NEJM19991138340107

31. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology (2004) 80:51–6. doi:10.1159/000080742

32. Vezzosi DJ, Bennett A, Rochaix P, Courbon F, Selves J, Pradere B, et al. Octreotide in insulinoma patients: efficacy on hypoglycaemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol (2005) 152:757–67. doi:10.1530/ej.1.19019

33. Hearns PR, Ahmed M, Woodhouse NJ. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review. Horm Res (1998) 29:211–3.

34. Hearns PR, Reynolds CL, Johansen K, Woodhouse NJ. Lung carcinoid with Cushings syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin), Clin Endocrinol (Oxf) (1988) 28:181–5.

35. Tanaka Y, Funahashi H, Imai T, Naruse T, Sazumura K, Oda Y. The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surg Today (2000) 30:541–3. doi:10.1007/s0059700007124

36. Verschoor L, Uitterlinden P, Lamberts SW, Del Pozo E. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol (Oxf) (1986) 25:555–60. doi:10.1111/j.1365-2265.1986.tb03609.x

37. von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen H. Metabolic response of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res (2012) 31:245–8. doi:10.1186/1756-9966-31-245

38. Di Bartolomeo M, Bajetto E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer (1996) 77(2):444–7. doi:10.1002/(SICI)1097-0142(19960115)77:2<444::AID-CNCR25>3.0.CO;2-4

39. Delamont T, Necpynenko F, Rubin J, Erfichman J, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Ann J Gastroenterol (2008) 103(12):S75–83. doi:10.1111/j.1572-0241.2007.01643.x

40. Bauer W, Briner U, Doepchner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci (1982) 31(11):1313–40. doi:10.1016/0024-3205(82)90087-X

41. Rubin J, Ajani J, Schirmer V, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 17(2):600–6.
53. Ghafieri AA, Choijacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPoma: subject review and one institutional experience. J Gastrointest Surg (2007) 12:382–93. doi:10.1007/s11605-007-0177-0
54. Song S, Shi R, Li B, Liu Y. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas (2009) 38(7):811–4. doi:10.1097/MPA.0b013e3181b28c7c
55. Nakayama S, Yokote T, Kobayashi K, Hirata Y, Hiraiai T, Komoto I, et al. VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. Endocrine (2009) 35:143–6. doi:10.1007/s12020-009-9146-6
56. Schally AV. Oncological applications of somatostatin analogues. Cancer Res (1988) 48:6977–85.
57. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med (1998) 217:143–52. doi:10.3181/00372727-217-44216
58. Weckbecker G, Raufu F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther (1993) 60:245–64.
59. Freidevaux S, Eberle AN. Somatostatin analogs and radiopharmaceuticals in cancer therapy. Bioisotopes (2002) 66:161–83. doi:10.1002/bip.10256
60. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab (2004) 15:300–10. doi:10.1016/j.tem.2004.07.002
61. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin analogs. Mol Cell Endocrinol (2007) 282:230–7. doi:10.1016/j.mce.2008.02.002
62. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol (2000) 12:368–77. doi:10.1097/00001849-200007000-00015
63. Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) (1988) 109:108–14.
64. Smis AA, Bellastella A, Prezioso D, Nicchio MR, Lotti T, Salvatore M, et al. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostatic and prostate cancer. J Clin Endocrinol Metab (1997) 82(8):2556–9. doi:10.1210/jc.82.8.25566
65. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnostic: an overview. Chemotherapy (2001) 47:1–29. doi:10.1159/000049157
66. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, et al. Octreotide as an antiproliferative agent in rat insulinoma positive for somatostatin receptors type 2. Endocrine (1996) 8:253–60. doi:10.1007/BF00656838
67. Eberle AN, Froidevaux S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of a somatostatin analogue in a patient with VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. Endocrine (2009) 35:143–6. doi:10.1007/s12020-009-9146-6
68. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisis A, Bocci G, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res (1997) 3:265–72.
69. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs (1997) 15:77–86. doi:10.1023/A:1005777413202
70. Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic carcinoid carcinoma. Ann Oncol (2008) 16:871–9. doi:10.1093/annonc/mdn213
71. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion (1993) 54:72–5. doi:10.1159/000201081
72. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning ME, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic gastroenteropancreatic tumours. Gut (1996) 38:450–8. doi:10.1136/gut.38.3.430
73. Saitz I, Trochanowski B, Buckley M, Hefferman B, Niedziwbecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumours. Cancer (1993) 72:244–8. doi:10.1002/1097-0142(19930701)72:1<244::AID-CNCR2827020143>3.0.CO;2-Q
74. Vliegen P, Fidlon F, Mianelli F, Sciuto R, Maini CL, Capurso G, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic carcinoid carcinoma. Ann Oncol (2008) 16:746–9. doi:10.1093/annonc/mdj113
75. Sais S, Scherubl H, Rieken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumours of the gastroenteropancreatic system. Recent Results Cancer Res (1996) 142:193–207. doi:10.1007/978-3-642-80035-1_12
76. Velan SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol (2004) 151:107–12. doi:10.1530/eje.0.1510107
77. Arnold R, Linke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumours: a randomized trial. Clin Gastroenterol Hepatol (2005) 3:761–71. doi:10.1038/clg.2005.82
78. Linke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol (2009) 27:4566–63. doi:10.1200/JCO.2009.22.8510
79. Shojamans H, Girbil F, Louie A, Oyaburu IV, Bashir S, Abou-Saf A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer (2002) 94:331–43. doi:10.1002/cncr.10195
80. Prommegger B, Lauf B, Eseringer C, Sauber T, Profanter C, Knoflach M, et al. Gastrointestinal carcinoid type 1 tumour: new diagnostic and therapeutic method. Eur J Gastroenterol Hepatol (2003) 15:705–7. doi:10.1097/00042737-200306000-00020
81. Fykse V, Sandvik AK, Qvistgård T, Falkmer SE, Syversen U, Walldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Sand J Gastroenterol (2004) 39:621–8. doi:10.1080/003655204100055225
82. Dworakowska D, Wlodek E, Leoncini C, Igreja S, Cakir M, Teng M, et al. Activation of Ral/MEK/ERK and PI3K/Akt/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer (2009) 16(4):1329–38. doi:10.1677/ERC-09-0101
83. Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptor type 2. Horm Res (2006) 65:120–5. doi:10.1159/0001090140
84. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa‘I Y, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol (2005) 11:2041–4.
the somatostatin analogue Sandostatin: a phase II study including endocrine effects. *Br J Cancer* (1990) **62**:627–30. doi:10.1038/bjc.1990.343

93. Rennullo A, Accardo G, Esposito D, De Bellis A, Bizzarro A, Romano M, et al. Hashimoto’s thyroiditis and ECL hyperplasia: early detection and SST analog treatment. *Eur J Inflamm.* (2013). (in press).

94. Ducrèux M, Ruszniewski P, Chavyvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. *Am J Gastroenterol.* (2000) **95**:3276–81. doi:10.1111/j.1572-0241.2000.03210.x

95. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, et al. Anti-tumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. *Eur J Cancer* (2001) **37**:1014–9. doi:10.1016/S0959-8049(01)00073-9

96. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. *Eur J Nucl Mol Imaging* (2003) **30**:781–93. doi:10.1007/s00259-003-1184-3

97. O’Toole D, Saveau A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. *Eur J Endocrinol.* (2006) **155**:849–57. doi:10.1530/eje.1.02307

98. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. *N Engl J Med* (2000) **343**:551–4. doi:10.1056/NEJM200008243430805

99. Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. *J Endocrinol Invest.* (2012) **35**(3):326–31. doi:10.3275/7869

100. Fjälling M, Andersson P, Forsell-Aronsson E, Grétarsdóttir J, Johansson V, Tiselius A, et al. Systemic radiouclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. *J Nucl Med* (1996) **37**:1519–21.

101. Heppeler A, Froodevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. *Curr Med Chem.* (2000) **7**:971–94. doi:10.2174/092986700374516

102. Forrer F, Valkema R, Kwékkéboom DJ, de Jong M, Krenning EP. Neuroendocrine tumours. Peptide receptor radiolocalisation and therapy. *Best Pract Res Clin Endocrinol Metab* (2007) **21**:111–29. doi:10.1016/j.beem.2007.01.007

103. de Jong M, Valkema R, Jamar F, Kools LK, Kwékkéboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radiouclide therapy of tumors: preclinical and clinical findings. *Semin Nucl Med* (2002) **32**(2):153–40. doi:10.1053/snuc.2002.31027

104. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radiouclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. *J Nucl Med* (2005) **46**(Suppl 1):135–75.

105. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. *Best Pract Res Clin Endocrinol Metab* (2005) **19**:265–76. doi:10.1016/j.beem.2004.11.016

106. Chan J, Kulke MK. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. *Expert Opin Emerg Drugs* (2007) **12**:253–70. doi:10.1517/14728214.12.2.253

107. Tiensuu Janson EM, Ahlström H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. *Eur J Cancer* (1992) **28**:627–30. doi:10.1016/0959-8049(92)90060-F

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 06 September 2013; paper pending published: 08 October 2013; accepted: 13 January 2014; published online: 07 February 2014.

Citation: Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A and Appetecchia M (2014) Somatostatin analogs treatment in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front. Endocrinol. 5:7. doi: 10.3389/fendo.2014.00007

This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology.

Copyright © 2014 Baldelli, Barnabei, Rizza, Isidori, Rota, Di Giacinto, Paoloni, Torino, Corsello and Lenzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.